Medication adherence and health care costs with the introduction of latanoprost therapy for glaucoma in a medicare managed care population

American Journal Geriatric Pharmacotherapy

Volumn 5, Issue 2, 2007, Pages 100-111

  Bhosle, Monali J ^a   Reardon, Gregory ^b   Camacho, Fabian T ^c   Anderson, Roger T ^c   Balkrishnan, Rajesh ^a  

^a OHIO STATE UNIVERSITY   (United States)

^b Informagenics LLC   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

elderly; glaucoma; medication adherence; open angle glaucoma

Indexed keywords

ANTIGLAUCOMA AGENT; APRACLONIDINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIMATOPROST; BRIMONIDINE; BRINZOLAMIDE; CARTEOLOL; DIPIVEFRINE; DORZOLAMIDE; DORZOLAMIDE PLUS TIMOLOL; LATANOPROST; LEVOBUNOLOL; METIPRANOLOL; TIMOLOL MALEATE; TRAVOPROST; UNOPROSTONE ISOPROPYL ESTER;

AGED; ARTICLE; BIVARIATE ANALYSIS; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG COST; DRUG EXPOSURE; DRUG USE; ELDERLY CARE; FEMALE; FOLLOW UP; HAZARD RATIO; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; MEDICARE; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

AGED; COHORT STUDIES; COSTS AND COST ANALYSIS; DRUG THERAPY, COMBINATION; FEMALE; GLAUCOMA; HEALTH CARE COSTS; HUMANS; INTRAOCULAR PRESSURE; MALE; MANAGED CARE PROGRAMS; MEDICARE; OCULAR HYPERTENSION; PATIENT COMPLIANCE; PROPORTIONAL HAZARDS MODELS; PROSTAGLANDINS F, SYNTHETIC; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TERMINOLOGY; TREATMENT OUTCOME;

EID: 34547932062     PISSN: 15435946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjopharm.2007.05.004     Document Type: Article

References (38)

1. Coleman A. Glaucoma. Lancet. 354 (1999) 1803-1810
2. Sommer A., Tielsch J., Katz J., et al. Racial differences in the cause-specific prevalence of blindness in east Baltimore. N Engl J Med. 325 (1991) 1412-1417
3. Rodriguez J., Sanchez R., Munoz B., et al. Causes of blindness and visual impairment in a population-based sample of US Hispanics. Ophthalmology 109 (2002) 737-743
4. Quigley H., and Vitale S. Models of open-angle glaucoma prevalence and incidence in the United States. Invest Ophthalmol Vis Sci. 38 (1997) 83-91
5. Infeld D., and O'Shea J. Glaucoma: Diagnosis and management. Postgrad Med J. 74 (1998) 709-715
6. Gordon M., and Kass M. The Ocular Hypertension Treatment Study: Design and baseline description of the participants. Arch Ophthalmol 117 (1999) 573-583
7. for the Eye Discases Prevalence Research Group. Friedman D., Wolfs R., O'Colmain B., et al. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 122 (2004) 532-538
8. Marquis R., and Whitson J. Management of glaucoma: Focus on pharmacological therapy. Drugs Aging 22 (2005) 1-21
9. Fiscella R. Costs of glaucoma medications. Am J Health Syst Pharm 55 (1998) 272-275
10. Polo V., Larrosa J., Ferreras A., and Honrubia F. Latanoprost vs combined therapy with timolol plus dorzolamide in open-angle glaucoma: A 24-month study. Ann Ophthalmol 37 (2005) 33-36
11. Xalatan [package insert] (2000), Pharmacia Corporation, Peapack, NJ
12. Lumigan [package insert] (2001), Allergan, Inc, Irvine, Calif Available at:http://www.fda.gov/cder/foi/label/2001/21275lbl.pdf. Accessed April 12, 2007
13. Travatan [package insert] (2001), Alcon Laboratories, Inc, Fort Worth, Tex
14. Xalatan [package insert] (2003), Pfizer Inc, New York, NY Available at: http://www.fda.gov/cder/foi/label/2001/20597s23lbl.pdf. Accessed April 12, 2007
15. Xalatan marks 10th anniversary. Prostaglandin glaucoma medication overcame obstacles (2006)
16. Waknine, Y. FDA approvals: Lumigan, cesamet, omnitrope. Medscape Medical News 2006 Available at:. http://www.medscape.com/viewarticle/540937 Accessed December 20 2006
17. DiMatteo M., Giordani P., Lepper H., and Croghan T. Patient adherence and medical treatment outcomes: A meta-analysis. Med Care 40 (2002) 794-811
18. CD000011. Haynes R., McDonald H., Garg A., and Montague P. Interventions for helping patients to follow prescriptions for medications. Cochrane Database Syst Rev. 2 (2002)
19. DiMatteo M. Variations in patients' adherence to medical recommendations: A quantitative review of 50 years of research. Med Care 42 (2004) 200-209
20. Rotchford A., and Murphy K. Compliance with timolol treatment in glaucoma. Eye 12 (1998) 234-236
21. Patel S., and Spaeth G. Compliance in patients prescribed eyedrops for glaucoma. Ophthalmic Surg 26 (1995) 233-236
22. Gurwitz J., Glynn R., Monane M., et al. Treatment for glaucoma: Adherence by the elderly. Am J Public Health 83 (1993) 711-716
23. Robin A., and Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy?. Ophthalmology 112 (2005) 863-868
24. Shaya F., Mullins C., Wong W., and Cho J. Discontinuation rates of topical glaucoma medications in a managed care population. Am J Manag Care 8 Suppl 10 (2002) S271-S277
25. Nordstrom B., Friedman D., Mozaffari E., et al. Persistence and adherence with topical glaucoma therapy. Am J Ophthalmol 140 (2005) 598-606
26. Balkrishnan R., and Anderson R. Predictive power of a risk-assessment questionnaire across different disease states: Results in an elderly managed care enrolled population. Am J Manag Care 7 (2001) 145-153
27. Choo P., Rand C., Inui T., et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to antihypertensive therapy. Med Care 37 (1999) 846-857
28. Steiner J., Koepsell T., Fihn S., and Inui T. A general method of compliance assessment using centralized pharmacy records. Description and validation. Med Care 26 (1988) 814-823
29. Balkrishnan R., Rajagopalan R., Camacho F., et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: A longitudinal cohort study. Clin Ther 25 (2003) 2958-2971
30. Shapiro S., and Wilk M. An analysis of variance test for normality. Biometrika 52 (1965) 591-611
31. Kennedy P. Estimation with correctly interpreted dummy variables in semilogarithmic equations. Am Econ Rev 71 (1981) 801
32. Manning W., and Mullahy J. Estimating log models: To transform or not to transform?. J Health Econ 20 (2001) 461-494
33. Schwartz G., Reardon G., and Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol 137 Suppl 1 (2004) S13-S16
34. Reardon G., Schwartz G., and Mozaffari E. Patient persistency with ocular prostaglandin therapy: A population-based, retrospective study. Clin Ther 25 (2003) 1172-1185
35. Wilensky J., Fiscella R., Carlson A., et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 141 Suppl 1 (2006) S28-S33
36. Dallas, Texas. Balkrishnan R., Bond J., Byerly W., et al. Compliance and costs associated with latanoprost therapy. Introduction in a managed care setting. Presented at: Annual Meeting of American Academy of Ophthalmology. October 22-25 (2000)
37. Balkrishnan R., Bond J., Byerly W., et al. Medication-related predictors of health-related quality of life in glaucoma patients enrolled in a Medicare health maintenance organization. Am J Geriatr Pharmacother 1 (2003) 75-81
38. Balkrishnan R., and Christensen D. A comparison of medication adherence indices to assess long-term inhaled corticosteroid medication use. J Asthma 38 (2001) 91-98